ShangBay Capital focuses its investments on early-stage opportunities within the medical device, biopharma, and healthcare technology sectors, particularly those addressing significant unmet clinical needs. Their strategy involves actively partnering with founders, leveraging their extensive industry experience and network to help commercialize products, navigate regulatory approvals, and expand market reach.
75% of their portfolio is in Healthcare. Average disclosed round size is $50.2M (across 8 rounds with reported amounts).
Portfolio
8
Fund Size
$2B
Top Stage
Series B
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
8 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Avation Medical | Series C | $22M | Feb 2024 |
 Laplace Interventional Inc. | Series B | $12.9M | Jul 2023 |
 Noah Medical | Series B | $150M | Apr 2023 |
| AAqua Medical | Series A | $8.2M | Sep 2020 |
 Zeto, Inc. | Series A | $7.3M | Mar 2020 |
| ZZAP Surgical Systems, Inc. | Growth | $81M | Jan 2020 |
 Berkeley Lights, Inc. | Growth | $95M | Oct 2018 |
 Refuge Biotechnologies, Inc. | Series B | $25M | May 2018 |
Top Co-Investors
Sequoia China2 shared
Danhua Capital1 shared
3E Bioventures Capital1 shared
WuXi Healthcare Ventures1 shared
Sequoia Capital1 shared
Cota Capital1 shared
Atinum Investment1 shared
Seraph Group1 shared
Aphelion Capital1 shared
SV Investment1 shared
SoftBank Vision Fund1 shared
Prosperity7 Ventures1 shared
Tiger Global Management1 shared
Hillhouse Capital1 shared
UpHonest Capital1 shared
LYFE Capital1 shared
1955 Capital1 shared
AME Cloud1 shared
Primavera Capital1 shared
Foxconn1 shared
Last updated: 16 April 2026